Is Buying Haemonetics Corporation (HAE) Here a Winning Strategy?

April 17, 2018 - By Robert Sims

Haemonetics Corporation (NYSE:HAE) Logo

Investors sentiment decreased to 1.11 in Q4 2017. Its down 0.17, from 1.28 in 2017Q3. It turned negative, as 20 investors sold Haemonetics Corporation shares while 77 reduced holdings. 48 funds opened positions while 60 raised stakes. 50.89 million shares or 3.15% less from 52.55 million shares in 2017Q3 were reported.
Van Berkom And Assoc Inc holds 973,593 shares or 1.84% of its portfolio. Employees Retirement Association Of Colorado, a Colorado-based fund reported 9,214 shares. Invesco Limited holds 361,769 shares or 0.01% of its portfolio. Schroder Inv Mgmt Group accumulated 20,869 shares. Ngam L P reported 0.02% stake. Gru reported 42,271 shares stake. Rhumbline Advisers invested 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE). Price T Rowe Assocs Md invested in 0.01% or 1.52M shares. Susquehanna Intll Gp Ltd Liability Partnership holds 4,059 shares. Riverhead Capital holds 4,671 shares or 0.01% of its portfolio. D E Shaw And accumulated 20,508 shares or 0% of the stock. Glenmede Na invested in 290 shares. Assetmark accumulated 0% or 83 shares. Sg Americas Llc accumulated 6,086 shares. Brinker Inc reported 5,687 shares.

Since January 2, 2018, it had 0 insider buys, and 3 selling transactions for $484,765 activity. KROLL MARK W also sold $448,434 worth of Haemonetics Corporation (NYSE:HAE) on Tuesday, January 2. The insider Basil Michelle L sold 389 shares worth $28,097.

The stock of Haemonetics Corporation (NYSE:HAE) reached all time high today, Apr, 17 and still has $77.22 target or 3.00 % above today’s $74.97 share price. This indicates more upside for the $4.01B company. This technical setup was reported by If the $77.22 PT is reached, the company will be worth $120.21 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.29% or $0.22 during the last trading session, reaching $74.97. About 140,755 shares traded. Haemonetics Corporation (NYSE:HAE) has risen 82.56% since April 17, 2017 and is uptrending. It has outperformed by 71.01% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 14. They expect $0.43 EPS, up 10.26 % or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.98M for 43.59 P/E if the $0.43 EPS becomes a reality. After $0.62 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65 % negative EPS growth.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 4 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Haemonetics Corp had 9 analyst reports since November 8, 2017 according to SRatingsIntel. The stock of Haemonetics Corporation (NYSE:HAE) earned “Buy” rating by Jefferies on Thursday, December 21. The stock of Haemonetics Corporation (NYSE:HAE) has “Buy” rating given on Monday, January 8 by Jefferies. The rating was upgraded by Raymond James on Tuesday, January 2 to “Market Perform”. The stock of Haemonetics Corporation (NYSE:HAE) has “Hold” rating given on Wednesday, November 8 by Craig Hallum. The firm earned “Buy” rating on Wednesday, February 7 by Jefferies. The firm earned “Equal-Weight” rating on Thursday, November 9 by Morgan Stanley. The stock of Haemonetics Corporation (NYSE:HAE) has “Overweight” rating given on Wednesday, February 7 by Morgan Stanley. Morgan Stanley upgraded the shares of HAE in report on Tuesday, January 2 to “Overweight” rating. On Wednesday, March 28 the stock rating was maintained by Morgan Stanley with “Buy”.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.01 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: